SAB BIOTHERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
SAB BIOTHERAPEUTICS, INC. (SABS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $7.25M, a 1055.82% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.46M, a 790.70% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $800.76K, a 23.65% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $627.00K, a 4.25% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $5.21M, a 77.12% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.94M, a 21.38% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.42M, a 9.37% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.67M, a 15.53% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $7.25M 10-Q · filed 2026-08-06 | $12.71M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $5.46M 10-Q · filed 2026-08-06 | $5.46M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $5.21M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $800.76K 10-Q · filed 2025-11-14 | $1.43M derived: sum of 2 quarters · filed 2026-08-06 | $2.04M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $627.00K 10-Q · filed 2026-08-06 | $627.20K 10-Q · filed 2025-08-07 | $1.24M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $613.00K 10-Q · filed 2026-08-06 | $612.95K 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $2.94M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $1.05M 10-Q · filed 2025-11-14 | $1.65M derived: sum of 2 quarters · filed 2025-11-14 | $2.27M derived: sum of 3 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $601.43K 10-Q · filed 2025-11-14 | $1.22M derived: sum of 2 quarters · filed 2025-11-14 | |||
| 2024-03-31 | $617.45K 10-Q · filed 2025-11-14 | ||||
| 2023-12-31 | $2.42M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $639.25K 10-Q · filed 2024-11-06 | $1.28M derived: sum of 2 quarters · filed 2024-11-06 | $1.89M derived: sum of 3 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $644.82K 10-Q · filed 2024-11-06 | $1.25M derived: sum of 2 quarters · filed 2024-11-06 | |||
| 2023-03-31 | $602.78K 10-Q · filed 2024-11-06 | ||||
| 2022-12-31 | $2.67M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $578.20K 10-Q · filed 2023-11-13 | $1.15M derived: sum of 2 quarters · filed 2023-11-13 | $2.05M derived: sum of 3 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $569.86K 10-Q · filed 2023-11-13 | $1.47M derived: sum of 2 quarters · filed 2023-11-13 | |||
| 2022-03-31 | $897.60K 10-Q · filed 2023-11-13 | ||||
| 2021-12-31 | $2.31M 10-K/A · filed 2023-04-28 | ||||
| 2021-09-30 | $880.66K 10-Q · filed 2022-11-14 | $1.31M derived: sum of 2 quarters · filed 2022-11-14 | $1.66M derived: sum of 3 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $433.43K 10-Q · filed 2022-11-14 | $782.55K derived: sum of 2 quarters · filed 2022-11-14 | |||
| 2021-03-31 | $349.12K 10-Q · filed 2022-11-14 | ||||
| 2020-12-31 | $1.30M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |